Roche trials database

Trial information

ESP Study: A Study to Assess the Effect of Adding Fuzeon (Enfuvirtide) to an Antiretroviral Regimen in Fuzeon-Naive Patients With Sustained HIV Viral Suppression.

Status:

Terminated

Protocol number:

ML19355

Sponsor:

Hoffmann-La Roche

Company division:

Pharmaceutical

Official Scientific Title:

A randomized, open label study to determine the immunological benefits of adding Fuzeon to an antiretroviral regimen in HIV-infected Fuzeon-naïve patients with sustained HIV viral suppression

Brief summary:

This 2 arm study will assess the immunological benefits of adding Fuzeon to an antiretroviral regimen in HIV-infected, Fuzeon-naive patients with a CD4 cell count <250 cells/mm3 and an HIV RNA viral load <400 copies/mL. Eligible patients will be randomized to receive Fuzeon 90mg bid sc in addition to their current antiretroviral therapy, or to continue their current antiretroviral therapy alone. The anticipated time on study treatment is 3-12 months, and the target sample size is <100 individuals. Target sample size is 40.

Study phase:

IV

Study type:

Interventional; Treatment; Randomized; Open Label; Active; Parallel; Safety/efficacy study

Conditions:

• HIV Infections

Intervention type:

Drug

Intervention name:

enfuvirtide [Fuzeon]

Primary outcome:

1. Mean change in CD4 cell count from baseline Time frame: Week 24

Key secondary outcomes:

1. Change in HIV RNA from baseline Time frame: Week 24
2. Change in HIV RNA and CD4 cell count Time frame: Weeks 24-48
3. Correlation between CD4 count and HIV RNA; OIs; QoL; ADEs; SAEs. Time frame: Throughout study

Inclusion criteria:

• adult patients, >=18 years of age;
• documented chronic HIV infection;
• currently receiving a stable antiretroviral regimen;
• CD4 cell count <250 cells/mm3;
• HIV RNA viral load <400 copies/mL for >12 months.

Exclusion criteria:

• prior exposure to Fuzeon;
• prior non-adherence to antiretroviral treatment regimens;
• active opportunistic infection;
• currently taking, or anticipated to take during the study, any immunomodulator.

Gender:

Males or Females

Age limits:

Min: 18 years Max: N/A (No limit)

Accepts healthy volunteers:

No

Trial registration date:

01.02.2007

Date last updated:

22.01.2010

This trial was conducted at the following locations:

Australia

• CARLTON
• DARLINGHURST
• MELBOURNE
• MIAMI
• PERTH
• SOUTH YARRA
• SYDNEY

Link to trial result